Hippocampal Proliferation Is Increased in Presymptomatic Parkinson’s Disease and due to Microglia

Doorn, K.J.; Drukarch, B.; van Dam, A.-M.; Lucassen, P.J.

DOI
10.1155/2014/959154

Publication date
2014

Document Version
Final published version

Published in
Neural Plasticity

Citation for published version (APA):
Doorn, K. J., Drukarch, B., van Dam, A-M., & Lucassen, P. J. (2014). Hippocampal Proliferation Is Increased in Presymptomatic Parkinson’s Disease and due to Microglia. Neural Plasticity, 2014, 959154. https://doi.org/10.1155/2014/959154
Hippocampal Proliferation Is Increased in Presymptomatic Parkinson’s Disease and due to Microglia

Karlijn J. Doorn,1,2 Benjamin Drukarch,2 Anne-Marie van Dam,2 and Paul J. Lucassen1

1 Swammerdam Institute for Life Sciences (SILS), Center for Neuroscience, University of Amsterdam (UvA), Science Park 904, 1098 XH Amsterdam, The Netherlands
2 Neuroscience Campus Amsterdam (NCA), Free University (VU) Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

Correspondence should be addressed to Paul J. Lucassen; p.j.lucassen@uva.nl

Received 13 May 2014; Accepted 1 July 2014; Published 14 August 2014

1. Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting 1-2% of the elderly population [1]. In addition to the well-known motor problems of PD patients, that are related to nigrostriatal dopamine deficits, also nonmotor symptoms are common. These symptoms strongly affect quality of life of PD patients as they include autonomic dysfunction, sleep problems, cognitive and neuropsychiatric changes [2–5], all changes unrelated to degeneration of the substantia nigra (SN). Apart from dopaminergic cell loss, the deposition of α-synuclein is a prominent neuropathological hallmark of PD. According to the staging concept described by Braak, α-synuclein deposition spreads over the brain in an anatomically predictable manner [6]. This coincides with the occurrence of nonmotor symptoms and can be observed already in early stages of PD, that is, in incidental Lewy body disease (iLBD) [7]. Moreover, α-synuclein can activate microglial cells, and neuroinflammatory responses are indeed important pathological features of PD [8–10].

Accumulation of α-synuclein has been reported in the hippocampus (HC), which may contribute to the cognitive and depressive changes that represent prominent nonmotor symptoms in PD [11, 12] (Figure 1). Of interest, the HC is also one of the few brain regions where stem cells reside. In the hippocampal subgranular zone (SGZ), stem cells undergo proliferation before they migrate through the granular cell layer (GCL), where they eventually become newborn, functional neurons that contribute to network function. In addition to this unique process of adult neurogenesis, which is largely confined to the DG, stem cells in the HC can proliferate and respond to neurodegenerative conditions.
For instance, overexpression of α-synuclein in PD models induces aberrant differentiation of neural progenitors and alters cellular plasticity in the hippocampus [13–15]. Also striatal deafferentation, or the loss of dopaminergic neurons, affects both neurogenesis [16] and proliferation in the HC [17]. In addition, several Parkinson-related pathogens induce degeneration of human neural stem cells (NSCs) [18] or reduce neurogenesis [19]. Stimulation of cellular plasticity on the other hand, for example through exercise, antidepressant treatment or high frequency stimulation, reverses impairments in neurogenesis in PD models [20] and may even benefit PD patients [21, 22].

The discovery that the human brain contains stem cells has instigated extensive research into their proliferative responses during neurodegeneration and into their potential for brain repair. In related animal models for Alzheimer’s disease (AD), changes in cellular plasticity and proliferation appear to depend on the extent of pathology and the severity of the disorder [23]. Regarding PD, stem cells and related cellular plasticity markers are also altered in relevant animal models [24–26], but only few studies exist on proliferative changes in human PD brain [26], most of which have focused on the SN [27, 28] and subventricular zone (SVZ) [29, 30]. In the human SN and SVZ, discrepant results have been obtained between different studies, and this topic remains subject of debate [26, 29, 31–34].

Thus far, little attention has been paid to cellular proliferative changes in the human HC, a brain region relevant for nonmotor symptoms in PD, like cognitive and depressive changes. Moreover, besides proliferation of NSCs, glial cells within the CNS may also proliferate in response to neuropathological changes. Indeed, in the AD hippocampus or in experimental multiple sclerosis, for example, proliferation of CNS resident microglia has been observed [35, 36]. Here, we first studied proliferative changes in prodromal and established cases of PD and, given the differential α-synuclein deposition, we include both the CA (nonneurogenic) and the DG (neurogenic) subregions. As activated microglial cells are present in the HC in PD and implicated in PD pathogenesis [9, 37], we also questioned whether microglial cells proliferate in these conditions. We selected hippocampal tissue of well-established and neuropathologically confirmed PD patients (Braak PD stages 4–6), matched control subjects (Braak PD stage 0), and incidental Lewy body disease (iLBD) cases (Braak PD stages 1–3) (Figure 1). As these latter cases lacked clinical symptoms of PD during their lives and did not receive dopaminergic medication, but displayed a neuropathological Braak α-synuclein deposition at autopsy [7], they can be considered a presymptomatic and prodromal state of PD. To assess cell proliferation, we used the well validated marker minichromosome maintenance protein 2 (MCM2) [38, 39] and colabeled it with the microglial marker Iba1 to investigate...
to what extent cell proliferation in the HC is accounted for by microglia.

2. Material and Methods

2.1. Postmortem Brain Tissue. Human postmortem hippocampal tissue was obtained from the Netherlands Brain Bank (NBB, Amsterdam, The Netherlands). In compliance with all local ethical and legal guidelines, informed consent for brain autopsy and the use of brain tissue and clinical information for scientific research was given by either the donor or the next of kin. Fourteen clinically diagnosed and neuropathologically verified PD patients (Braak PD stages 4–6) were selected as well as six clinically healthy controls without neurological or psychiatric disease, that displayed some PD α-synuclein pathology at autopsy (Braak PD stages 0–3) and were classified as iLBD cases. For the control group, nine healthy subjects without neurological or psychiatric disease and without any α-synuclein pathology (Braak PD stage 0) were included. The three groups were matched for gender and age; age of the control subjects ranged from 62 to 92 years, in the iLBD cases from 56 to 91, and in the PD patients from 59 to 96. All subjects were matched for postmortem delay and cerebrospinal fluid pH value. Donors who died of sepsis or stroke were excluded. Also Braak neurofibrillary tangles (NFT) and amyloid-beta (Aβ) plaques scores were matched between control subjects, iLBD cases, and PD patients, ruling out any possible difference in proliferation due to differences in AD pathology. The clinicopathological data of the patients and the Braak staging for PD and AD of all donors is summarized in Table 1. Braak scores for AD and PD neuropathology were provided by the NBB and had been obtained after careful neuropathological evaluation of disease-relevant brain areas by experienced neuropathologists. The density and distribution of LBs/LNs, NFT, and Aβ plaques were determined using classic Bodian staining and immunohistochemistry for α-synuclein (Clone KM51, Novacastra, Bioconnect BV) and hyperphosphorylated tau (Clone AT8, Pierce, Rockford, IL) and Aβ (Clone 6F/3D, DAKO, DakoCytomation BV), respectively.

2.2. Tissue Processing. At autopsy, brain regions were dissected and immersion-fixed in 4% formaldehyde for four weeks, after which they were embedded in paraffin. From the paraffin blocks that contained the HC, 10-micrometer (μm) sections were cut on a microtome, mounted, and dried in a stove overnight at 37°C before immunohistochemical analysis. Sections were mounted on positively charged glass slides (Menzel-Gläser SuperFrost Plus, Braunschweig, Germany).

2.3. Validation of MCM2 as Proliferation Marker in Human Brain Tissue. Various markers are available to identify cell proliferation or specific phases of the cell cycle in human postmortem brain tissue [39–42]. Of these, the minichromosome maintenance protein 2 (MCM2) is involved in the control of DNA replication and commonly used in cancer research as a reliable marker for detecting dividing and slowly cycling putative stem cells in situ [38, 43, 44]. MCM2 expression starts in early G1 and is maintained throughout the cell cycle, also in cells that proliferate without actually synthesizing DNA, and is thus present in higher numbers than, for example, the short-lived proliferation marker Ki-67 [38, 45, 46]. Moreover, the majority of the cells that express MCM2 coexpress the immature neuronal marker doublecortin [42] and MCM2 was therefore also used to study cellular plasticity in comparable tissues. Various tests to validate and confirm specificity of MCM2 and related markers have been performed by us and others before [38, 46, 47], for example, on samples of young rat brain and human colon, that were processed and embedded in the exact same way as the human brain tissue used in the current study [39, 41].

2.4. MCM2 Immunohistochemistry. Sections were heated in a stove for one hour at 56°C, before they were deparaffinized in xylene and rehydrated through a graded series of ethanol (100%, 96%, 90%, and 70%, resp.) and TBS. For subsequent antigen retrieval, sections were rinsed in 10 mM Tris buffer (pH 9.0) containing 1 mM EDTA (Tris-EDTA) and afterwards placed in preheated Tris-EDTA buffer in a steamer at 90–99°C for 30 minutes. After pretreatment, the sections were allowed to regain room temperature (RT), rinsed in Tris-buffered saline (TBS, pH 7.6), and incubated for 20 min in TBS containing 0.3% H₂O₂ and 0.1% sodium azide to block endogenous peroxidase activity. Nonspecific binding was blocked with 5% nonfat dried milk in TBS containing 0.5% Triton (TBS-T, pH 7.6; blocking solution) for 30 min at RT. Subsequently, sections were incubated overnight at 4°C with mouse anti-MCM2 (BM28, BD Transduction Lab 610700, mouse 1:600). Sections were then washed in TBS and incubated for 2 hr at RT in biotinylated goat anti-mouse IgGs (1:400; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) followed by HRP-labeled avidin-biotin complex (ABC complex, 1:400; Vector Laboratories, Burlingame, CA, USA) in TBS-T for 1 hr at RT. MCM2 staining was visualized using 3,3-diaminobenzidine (DAB, Sigma, St. Louis, USA) and counterstained with hematoxylin. After dehydration in graded ethanol solutions, sections were cleared in xylene and coverslipped in Entellan (Merck).

2.5. Immunofluorescence. For double-immunofluorescent labeling of microglial cells and MCM2 expression, Iba1 (WAKO chemicals, 019-19741, rabbit, 1:300) and MCM2 (1:1000) were used. Sections were pretreated with Tris-EDTA (pH 9.0) and primary antibodies were diluted in the blocking solution, as indicated above. After an overnight incubation at 4°C, the sections were washed and subsequently incubated for 2 h at RT with donkey anti-rabbit Alexa Fluor 488 labeled donkey anti-rabbit IgGs (Iba1) and biotinylated goat anti-mouse IgGs (MCM2) (1:400, Jackson ImmunoResearch, West Grove, PA, USA), followed by ABC complex (1:800) for 1 h and biotinylated tyramide enhancement in TBS for 20 min. Thereafter, sections were incubated with Alexa Fluor 594 labeled streptavidin (1:800, Jackson ImmunoResearch, West Grove, PA, USA). After washing, sections were coverslipped
### Table 1: Clinical and neuropathological information of all included subjects.

| C. number | Sex | Age | PMD (hrs.) | Braak staging | D | Region | Cause of death |
|-----------|-----|-----|------------|---------------|---|--------|----------------|
| 1         | F   | 92  | 7:00       | 1A            | 0 | NDC    | HC             | Acute death, pulmonary emboli |
| 2         | M   | 88  | 4:23       | 2A            | 0 | NDC    | HC             | Gastrointestinal bleeding     |
| 3         | F   | 84  | 6:55       | 1O            | 0 | NDC    | HC             | Myelodysplasia                |
| 4         | M   | 82  | 5:10       | 1O            | 0 | NDC    | HC             | Unknown                       |
| 5         | F   | 62  | 7:20       | 1O            | 0 | NDC    | HC             | Unknown                       |
| 6         | F   | 83  | 3:20       | 1B            | 0 | NDC    | HC             | Legal Euthanasia              |
| 7         | F   | 84  | 4:45       | 1O            | 0 | NDC    | HC             | Heart failure                 |
| 8         | F   | 85  | 5:19       | 2B            | 0 | NDC    | HC             | Natural death, pulmonary disease |
| 9         | M   | 78  | <17:00     | 1O            | 0 | NDC    | HC             | Heart failure                 |
| 10        | F   | 82  | 5:10       | 2O            | 2 | iLBD   | HC             | Heart failure                 |
| 11        | M   | 86  | 4:00       | 2B            | 1 | iLBD   | HC             | Respiratory insufficiency      |
| 12        | M   | 56  | 5:00       | 0 (—)         | 2 | iLBD   | HC             | Pneumonia                     |
| 13        | F   | 91  | 4:50       | (—)           | 1 | iLBD   | HC             | Exhaustion, colon carcinoma   |
| 14        | M   | 84  | 7:20       | 1B            | 3 | iLBD   | HC             | Prostate cancer               |
| 15        | M   | 87  | 10:20      | 1A            | 1 | iLBD   | HC             | Pneumonia, heart failure       |
| 16        | M   | 83  | 4:50       | 1A            | 4 | PDD    | HC             | Heart failure                 |
| 17        | F   | 59  | 9:35       | 1A            | 4 | PD     | HC             | Shock due to blood loss in digestive tract |
| 18        | F   | 90  | 4:50       | 1B            | 4 | PDD    | HC             | Unknown                       |
| 19        | F   | 70  | 7:05       | 2B            | 6 | PDD    | HC             | Haematemesis by oesophagitis  |
| 20        | M   | 84  | 9:00       | 1A            | 5 | PDD    | HC             | Pneumonia and dehydration    |
| 21        | F   | 87  | 5:25       | 2B            | 6 | PDD    | HC             | Pneumonia                     |
| 22        | M   | 73  | 5:35       | 1A            | 5 | PDD    | HC             | Direct cause unknown (morphine)|
| 23        | M   | 83  | 5:15       | 1B            | 6 | PDD    | HC             | Pneumonia                     |
| 24        | F   | 84  | 7:25       | 2B            | 5 | PD     | HC             | Old age, shortness of breath  |
| 25        | F   | 96  | 7:10       | 1B            | 5 | PD     | HC             | Old age                       |
| 26        | M   | 86  | 5:10       | 2B            | 5 | PD     | HC             | Heart failure                 |
| 27        | M   | 71  | 5:50       | 1A            | 6 | PD     | HC             | Respiratory failure           |
| 28        | F   | 83  | 6:05       | 1O            | 4 | PDD    | HC             | Cachexia by dementia, infarction |
| 29        | M   | 83  | 6:35       | 1B            | 6 | PDD    | HC             | Pneumonia                     |

D: clinical diagnosis; PMD: postmortem delay; NFT: neurofibrillary tangles; Aβ: amyloid-beta; α-syn: alpha-synuclein; NDC: nondemented control subject; iLBD: incidental Lewy Body disease; PD: Parkinson's disease; PDD: Parkinson's disease with dementia; HC: hippocampus.

2.6. Semiquantitative Analyses of MCM2-Positive Cells. For standardization purposes, hippocampal sections were collected only around the anterior to midlevel of the HC of every subject and only when large dentate gyrus (DG) and Cornu Ammonis (CA) subregions were both present. Furthermore, MCM2-positive cells were included in the subsequent analysis only when they displayed a clearly immature, mitotic, and/or migratory morphology, and were located in an isolated manner (Figure 2). Semiquantification was performed by assessing the numbers of MCM2-positive cells present in the five main HC grey matter regions, that is DG, CA4, CA3, CA2, and CA1, at a 10x magnification and then expressed per surface area (region of interest, ROI, 1 mm²) using CellF Olympus Soft Imaging Solutions GmbH software (Tokyo, Japan).

2.7. Statistics. Statistical analyses were performed using the SPPS package version 20.0 (Statistical Product and Service Solutions, Chicago, IL, USA). The mean and standard deviation of the number of MCM2-positive cells were calculated for each group and within each subject for all the different subregions of the HC. The data did not meet criteria for normal distribution; thus statistical analyses were performed using nonparametric tests. Statistical analysis was executed with the nonparametric Kruskal-Wallis test to examine main group effects between controls, iLBD, and PD patients. Subsequently, Mann-Whitney U tests were performed as post hoc tests. Results were considered significant if they fell below an alpha of $P \leq 0.016$, after Bonferroni correction. Within the same cases, statistical analyses for the different subregions of the HC were performed with the nonparametric related samples Friedman’s analysis to examine main region effects, followed by paired Wilcoxon tests as post hoc tests. Results were considered significant if they fell below an alpha of $P \leq 0.02$, family wise error- (FWE-) corrected.
3. Results

3.1. Increased Number of MCM2-Positive Cells in the HC of iLBD Cases. In the pyramidal layer and DG of the HC of all three patient groups, generally low numbers of MCM2-positive cells were found that displayed morphology typical for proliferating cells, such as a doublet shape and small size (Figure 2 and Figures 5(b), 5(e), and 5(h)). Except for a significant main effect in the number of MCM2-positive cells between the hippocampal subregions within the control group (Figure 3(a); \( P = 0.034 \), related samples Friedman’s analysis), no significant differences were found between the subregions within each of the 2 different patient groups (Figures 3(b) and 3(c)). Further analysis revealed a trend towards an increase in the DG compared to the CA3, CA4, and CA1 within the control group (Figure 3(a); resp., \( P = 0.043 \), \( P = 0.043 \), and \( P = 0.08 \); nonparametric Mann-Whitney \( U \) test, significance reached at alpha \( P \leq 0.02 \); FWE-corrected; Ctr DG mean = 2.45 ± 1.03; Ctr CA3 mean = 0.31 ± 0.21; Ctr CA4 mean = 0.35 ± 0.25; Ctr CA1 mean = 0.93 ± 0.56).

Taking all data together revealed a significant increase in the number of MCM2-positive cells in the total hippocampal grey matter (CA1-CA4, DG combined) in the iLBD cases compared to control subjects (Figure 4(a); \( P = 0.004 \); nonparametric Mann-Whitney \( U \) test, significance reached at alpha \( P \leq 0.016 \), Bonferroni-corrected; Ctr mean = 5.21 ± 2.23; iLBD mean = 45.24 ± 25.29; PD mean = 26.51 ± 9.25). When analyzing the subregions separately, a significant main group effect was found for CA3 and CA4 between control subjects, iLBD cases, and PD patients (resp., \( P = 0.006 \), \( P = 0.16 \); nonparametric independent samples Kruskal-Wallis analysis). Further analysis revealed there was a significant increase in the number of MCM2-positive cells in the CA3 and CA4 of the iLBD cases compared to the CA3 and CA4 of control subjects (Figures 4(d) and 4(e); resp., \( P = 0.001 \), \( P = 0.003 \); nonparametric Mann-Whitney \( U \) test, significance reached at alpha \( P \leq 0.016 \), Bonferroni-corrected; Ctr CA3 mean = 0.31 ± 0.21; Ctr CA4 mean = 0.35 ± 0.25; iLBD CA3 mean = 13.05 ± 8.77; iLBD CA4 mean = 4.95 ± 1.67) and a trend towards an increase in the numbers of MCM2-positive cells in the other three hippocampal subregions of the iLBD cases compared to the control subjects (Figures 4(b), 4(c), and 4(f); Ctr CA1 mean = 0.93 ± 0.56; Ctr CA2 mean = 1.17 ± 0.62; Ctr DG mean = 2.45 ± 1.03; iLBD CA1 mean = 5.88 ± 3.17; iLBD CA2 mean = 14.82 ± 9.58; iLBD DG mean = 6.45 ± 4.04).

No significant differences were found between PD patients and control or iLBD cases in total HC or within any of the subregions (Figure 4).

3.2. Colocalization of MCM2 with Iba1 Microglial Cells in the HC. To determine whether microglia are proliferating, double immunofluorescence and confocal microscopical analysis revealed that the majority of MCM2-positive cells colocalized with Iba1-positive microglia (representative examples are shown in Figure 5). Of each patient group, 3 cases were double stained for Iba1 and MCM2 and the percentage coexpression was determined. In the control subjects, MCM2-positive cells were rare in the CA regions but always colocalized with Iba1 (100%). In iLBD cases, the highest number of MCM2-positive cells was present in the CA subregions. An average of 14 positive MCM2 cells were counted, of which an average of 13 were Iba1 positive, yielding 93% coexpression. In PD patients, fewer MCM2-positive cells were counted in CA regions compared to the iLBD group. An average of 6 positive MCM2 cells were counted, of which on average 5 were Iba1 positive, that is, 83%. In the DG, overall less MCM2-positive cells were counted; however, the percentages of colocalization with Iba1 were similar to CA regions. In general, quantification revealed >90% of the MCM2-positive cells in the HC to be microglia in control subjects, iLBD cases, and PD patients (representative examples are shown in Figures 5 and 6).

4. Discussion

We studied proliferating cells in the HC of control subjects, iLBD cases, and established PD patients. Using MCM2 as marker, no difference was observed in the amount of proliferating cells between control subjects and PD patients. However, in the presymptomatic iLBD cases, a clear increase in MCM2-positive cells was found. Interestingly, over 90% of the MCM2-positive cells were cocabeled with Iba1, indicating that microglial cells are the main proliferating cells in the HC of iLBD cases and PD patients.

In control subjects, the low number of MCM2-positive proliferating cells observed in the HC is consistent with the low rates of hippocampal proliferation and neurogenesis found before in the aged rodent, primate, and human HC.
and in comparable PD brain tissue [30, 41, 48–51]. Within the control group, MCM2-positive cells were increased in the DG compared to other hippocampal regions (Figure 3(a)), which was of interest as most proliferation was beforehand expected to occur in this subregion. Interestingly, the differences between the DG and other subregions were no longer present in the iLBD and PD groups, with higher numbers of proliferating cells in all subregions (Figures 3(b) and 3(c)), suggesting that the disease process has triggered additional proliferative responses also outside the DG, and in fact throughout the HC.

When total counts in the combined HC were compared between the three cohorts, significant increases in proliferation were found in the iLBD cases, but no difference was present between the PD group relative to the control group (Figure 4(a)). This was unexpected as, based on experimental studies, lowered dopamine levels were expected to reduce hippocampal proliferation. Also the increase in iLBD cases was unexpected as no clinical symptoms were present in this cohort (yet) and although not quantified, their dopamine levels are assumed to be unaltered. However, there is also some DAT-SPECT data that reflects a decrease of striatal dopamine levels and nigral degeneration already in the premotor stage of PD [52–54]. Whether these cases can be readily compared to our iLBD cases remains to be answered. Subdividing the different HC subregions revealed that the significant increase in the entire HC in iLBD was mainly due to the CA3 and CA4 and to a lesser extent to the CA2 subregion (Figures 4(c), 4(d), and 4(e)). Since iLBD can be considered a presymptomatic state of PD, this result suggests that an early and disease-related induction of proliferation occurs in the HC.

Although earlier studies suggested that proliferation outside neurogenic regions may reflect “endangered” neurons that attempt to reenter the cell cycle [55], there are no indications that proliferation in the CA subregions will actually give rise to new neurons. Also the current morphology, consistent with a proliferative phenotype, and the localization of the MCM2 cells, that is, closely apposed to a pyramidal neuron and thus suggestive of a “satellite” cell (Figure 2, arrowhead), hint that proliferation in nonneurogenic subregions likely reflects that of a nonneuronal cell type, for example,
Figure 4: MCM2-positive cell numbers in the total HC and different hippocampal subregions. (a) The total number of MCM2-positive cells in the HC was significantly higher in iLBD cases compared to control subjects ($^*P = 0.004$; nonparametric Mann-Whitney $U$ test). (b–f) Comparing MCM2 IR per HC subregion between the 3 different groups revealed a significant increase in number of proliferating cells in hippocampal areas (d) CA3 and (e) CA4 (resp., $^*P = 0.001$, $^*P = 0.003$; nonparametric Mann-Whitney $U$ test) of iLBD cases versus control subjects. Significance reached at alpha of $P \leq 0.016$, Bonferroni-corrected. Data represent mean ± SEM.
Figure 5: Colocalization of the majority of MCM2-positive cells with Iba1 in the hippocampal CA3 region of control subjects, iLBD cases and PD patients. (a–f) Representative confocal laser scanning microscopical images of double-immunofluorescent stained sections revealed that the majority of the MCM2-positive cells show colocalization with the microglial marker Iba1 (arrows in (c), (f), (i) and (j), and (k) and (l)). Iba1-positive microglia are depicted in green (a, d, and g) and MCM2 in red (b, e, and h). (j–l) Higher magnification of colocalization (l) between Iba1-positive microglia ((j), green) and MCM2 ((k), red); bar (a–i) = 40 μm; (j–l) = 10 μm.
Figure 6: Colocalization of the majority of MCM2-positive cells with Iba1 in the hippocampal DG region of control subjects, iLBD cases, and PD patients. (a–f) Representative confocal laser scanning microscopical images of double-immunofluorescent stained sections revealed that the majority of the MCM2-positive cells show colocalization with the microglial marker Iba1 (arrows in (c), (f), and (i)). (b, d) Control subject shows one MCM2-positive cell with no colocalization with Iba1 (arrowhead). Iba1-positive microglia are depicted in green (a, d, and g) and MCM2 in red (b, e, and h); bar (a–i) = 40 µm.

To confirm this, we used immunofluorescent colabeling of MCM2 with Iba1 and established that almost all proliferating cells in the PD HC represent microglia. The increase in iLBD cases relative to control subjects and PD patients suggests that proliferation of microglia occurs early in PD, prior to actual deposition of α-synuclein.

In most PD cases, neuronal populations in the HC show accumulation of α-synuclein [56, 57] which may activate the brain’s immune system through microglia activation [58]. It is still debatable whether neuronal α-synuclein inclusions (Lewy bodies/Lewy neurites) cause microglial activation and/or neuronal death, or whether LBs/LNs act as protective “containers” and that it is the extracellular α-synuclein oligomers and fibrils that are toxic and activate microglia. On the other hand, neurons containing α-synuclein inclusions could communicate with microglia and activate them by neuron to glia signaling. Indeed, activation of microglia has been repeatedly shown in PD. While different microglial
phenotypes are present in the SN, HC, and OB in PD, their functional role and hence the implications of microglial proliferation for PD etiology remain elusive [37, 59–61]. Similarly, the exact triggers for microglial proliferation are unknown. Transgenic mice overexpressing wild-type α-synuclein develop α-synuclein inclusions shortly after birth but show unchanged cell proliferation in their SVZ and HC at later ages [14, 62, 63]. In related prion disease models, proliferation of microglial cells is considered important in their turnover [64, 65] and to a larger extent to account for the expansion of the resident microglia population during, for example, prion disease development [66]. A related study on AD mouse models found changes in proliferation and microglia to coincide in time with increases in amyloid plaque load [67], suggesting that the accumulation of aberrant proteins like amyloid, and possibly also of α-synuclein, may trigger microglial proliferation.

While in vitro studies had already demonstrated that the aggregated form of α-synuclein can trigger microglial activation [10, 68], the HC of iLBD cases is largely devoid of α-synuclein depositions, and a role for soluble forms or α-synuclein oligomers can thus not be excluded. α-Synuclein oligomers can, for example, activate microglia via toll-like receptor-2 (TLR2) and thereby stimulate proinflammatory cytokine production [69, 70]. In agreement, in a separate study, we found TLR2 expression to be upregulated in the HC of iLBD cases [61].

In addition to increasing the cell population, an alternative, more speculative, interpretation of proliferation in microglia could be phagocytosis of α-synuclein. The release of α-synuclein and the subsequent uptake by neighboring neurons or glia suggest possibilities for cell-to-cell transfer and propagation that was recently proposed as conceptual model for proteinopathies [71, 72] and is consistent with the spatiotemporal progression of PD neuropathology over the brain [73]. Interestingly, neuron-to-glia transmission is accompanied by microglia activation [26, 74] and could thus underlie some of the proliferative changes observed in microglia in our current study. For instance, α-synuclein secreted by neurons is released into the extracellular space and can be taken up by microglia and phagocytosed. Several forms of α-synuclein have been found to induce microglial activation [10, 75, 76]. Similar to amyloid-beta, such secreted proteins can be “sensed” by microglia through toll-like receptors that could lead to the activation of inflammatory response genes and their proliferation [61, 69, 71, 77–79]. Another possibility is that proliferative changes reflect altered calcium signaling that was, for example, found to be dysregulated in microglia in close vicinity to amyloid plaques in AD brain [80]. These options are still speculative, and ongoing phagocytosis of α-synuclein inside microglia is technically difficult to visualize in postmortem human brain but may provide a possible explanation for the microglial proliferation we observed.

Our current hippocampal data are in contrast with a previous study on proliferation in the SVZ in PD and PD models [29], indicating that cell proliferation in the SVZ, and possibly also in the DG, may be under dopaminergic control [16, 29, 81, 82]. These authors used nestin and beta tubulin as markers and found significant reductions in proliferation in the HC of 3 PD patients and 5 PD patients with dementia, which they compared to 3 controls. Although different markers were used, we did not find any indication for a reduction in proliferation in the HC our cohorts, together comprising 20 patients and 9 controls. Another study on the SVZ failed to find differences in the proliferative capacity between controls and PD patients too [30]. While followed by an interesting debate [32, 33], this also suggested that proliferating progenitor cells are at least not reduced in PD. The methodological limitations that exist for visualization of neuronal proliferation in human postmortem brain [83–88] do not seem to hold explicitly for microglia proliferation. MCM2 can thus be used as a marker to determine also nonneuronal cell proliferation in human postmortem material.

In conclusion, the increase in numbers of proliferating cells in the HC of iLBD cases, a prodromal state of PD, but not in clinically established PD patients, indicates an early response to developing pathology in the PD HC. As almost all of the proliferating cells in the HC are microglia, this implies that neuroinflammatory processes may play an important role in ongoing PD pathology.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Anne-Marie van Dam and Paul J. Lucassen contributed equally to this paper.

Acknowledgments

The authors thank Dr. W. Van de Berg (Free University Amsterdam) and Dr. I. Huitinga and Mr. M. Kooreman of the Netherlands Brain Bank Amsterdam for provision and help with the human brain tissue. Paul J. Lucassen, Karlijn J. Doorn, and Anne-Marie van Dam are financially supported by the Internationale Parkinson Fonds (IPF); Paul J. Lucassen is supported by Alzheimer Nederland and the Internationale Stichting Alzheimer Onderzoek (ISAO).

References

[1] G. Alves, E. B. Forsaa, K. F. Pedersen, M. Dreetz Gjerstad, and J. P. Larsen, “Epidemiology of Parkinson’s disease,” Journal of Neurology, vol. 255, no. 5, pp. 18–32, 2008.
[2] D. Aarsland and M. W. Kurz, “The epidemiology of dementia associated with Parkinson’s disease,” Brain Pathology, vol. 20, no. 3, pp. 633–639, 2010.
[3] A. Gaenslen, I. Swid, I. Liepelt-Scarfone, J. Godau, and D. Berg, “The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease,” Movement Disorders, vol. 26, no. 4, pp. 653–658, 2011.
[4] L. T. Grinberg, U. Rueb, A. T. D. L. Alho, and H. Heinsen, "Brainstem pathology and non-motor symptoms in PD," *Journal of the Neurological Sciences*, vol. 289, no. 1-2, pp. 81–88, 2010.

[5] H. Braak, U. Rub, and K. Del Tredici, "Cognitive decline correlates with neuropathological stage in Parkinson’s disease," *Journal of the Neurological Sciences*, vol. 248, no. 1-2, pp. 255–258, 2006.

[6] H. Braak, K. Del Tredici, H. Bratza, J. Hamm-Clement, D. Sandmann-Keil, and U. Rub, "Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages)," *Journal of Neurology*, vol. 249, supplement 3, pp. 1–5, 2002.

[7] W. D. J. van de Berg, D. H. Hepp, A. A. Dijkstra, J. A. M. Rozemuller, H. W. Berendse, and E. Foncke, "Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson’s disease," *Parkinsonism & Related Disorders*, vol. 18, no. 1, pp. S28–S30, 2012.

[8] D. C. Wu, V. Jackson-Lewis, M. Vila et al., "Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease," *The Journal of Neuroscience*, vol. 22, no. 5, pp. 1763–1771, 2002.

[9] K. J. Doorn, P. J. Lucassen, H. W. Boddeke et al., "Emerging roles of microglial activation and non-motor symptoms in Parkinson’s disease," *Progress in Neurobiology*, vol. 98, no. 2, pp. 222–238, 2012.

[10] W. Zhang, T. Wang, Z. Pei et al., "Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease," *The FASEB Journal*, vol. 19, no. 6, pp. 533–542, 2005.

[11] Y. Lim, V. M. Kehm, E. B. Lee et al., "α-syn suppression reverses synaptic and memory defects in a mouse model of dementia with lewy bodies," *The Journal of Neuroscience*, vol. 31, no. 27, pp. 10076–10087, 2011.

[12] G. A. Carlesimo, F. Piras, F. Assogna, F. E. Pontieri, C. Caltagirone, and G. Spalletta, "Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study," *Neurology*, vol. 78, no. 24, pp. 1939–1945, 2012.

[13] B. Winner, D. C. Lie, E. Rockenstein et al., "Human wild-type α-synuclein impairs neurogenesis," *Journal of Neuropathology and Experimental Neurology*, vol. 63, no. 11, pp. 1155–1166, 2004.

[14] P. Desplats, B. Spencer, L. Crews et al., "α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of notch," *Journal of Biological Chemistry*, vol. 287, no. 38, pp. 31691–31702, 2012.

[15] B. Winner, Z. Kohl, and F. H. Gage, "Neurodegenerative disease and adult neurogenesis," *European Journal of Neuroscience*, vol. 33, no. 6, pp. 1139–1151, 2011.

[16] B. Winner, M. Geyer, S. Couillard-Despres et al., "Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb," *Experimental Neurology*, vol. 197, no. 1, pp. 113–121, 2006.

[17] K. Suzuki, K. Okada, T. Wakuda et al., " Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine," *PLoS ONE*, vol. 5, no. 2, Article ID e9260, 2010.

[18] G. H. Liu, J. Qu, K. Suzuki et al., "Progressive degeneration of human neural stem cells caused by pathogenic LRRK2," *Nature*, vol. 491, no. 7425, pp. 603–607, 2012.

[19] P. Desplats, P. Patel, K. Kosberg et al., "Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease," *Molecular Neurodegeneration*, vol. 7, no. 1, article 49, 2012.

[20] Z. Kohl, B. Winner, K. Uhbi et al., "Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model," *European Journal of Neuroscience*, vol. 35, no. 1, pp. 10–19, 2012.

[21] G. M. Petzinger, B. E. Fisher, S. McEwen, J. A. Beeler, J. P. Walsh, and M. W. Jakowec, "Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease," *The Lancet Neurology*, vol. 12, no. 7, pp. 716–726, 2013.

[22] O. Lamm, J. Ganz, E. Melamed, and D. Offen, "Harnessing neurogenesis for the possible treatment of Parkinson’s disease," *Journal of Comparative Neurology*, vol. 522, no. 12, pp. 2817–2830, 2014.

[23] M. W. Marllat and P. J. Lucassen, "Neurogenesis and Alzheimer’s disease: biology and pathophysiology in mice and men," *Current Alzheimer Research*, vol. 7, no. 2, pp. 113–125, 2010.

[24] C. D. Clelland, M. Choi, C. Romberg et al., "A functional role for adult hippocampal neurogenesis in spatial pattern separation," *Science*, vol. 325, no. 5937, pp. 210–213, 2009.

[25] G. C. O’Keeffe, R. A. Barker, and M. A. Caldwell, "Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain," *Cell Cycle*, vol. 8, no. 18, pp. 2888–2894, 2009.

[26] F. Marxreiter, M. Regensburger, and J. Winkler, "Adult neurogenesis in Parkinson’s disease," *Cellular and Molecular Life Sciences*, vol. 70, no. 3, pp. 459–473, 2013.

[27] K. Yoshimi, Y. Ren, T. Seki et al., "Possibility for neurogenesis in substantia nigra of parkinsonian brain," *Annals of Neurology*, vol. 58, no. 1, pp. 31–40, 2005.

[28] A. Bota and G. U. Höglinger, "Dopamine and adult neurogenesis," *Journal of Neurochemistry*, vol. 100, no. 3, pp. 587–595, 2007.

[29] G. U. Höglinger, P. Rizk, M. P. Muriel et al., "Dopamine depletion impairs precursor cell proliferation in Parkinson disease," *Nature Neuroscience*, vol. 7, no. 7, pp. 726–735, 2004.

[30] S. A. van den Berge, M. E. van Strien, J. A. Korecka et al., "The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain," *Brain*, vol. 134, no. 11, pp. 3249–3263, 2011.

[31] O. Arias-Carrión, E. Yamada, N. Freundlieb et al., "Neurogenesis in substantia nigra of parkinsonian brains?" *Journal of Neural Transmission. Supplementum*, vol. 73, pp. 279–285, 2009.

[32] G. U. Höglinger, R. A. Barker, T. Hagg, O. Arias-Carrión, M. A. Caldwell, and E. C. Hirsch, "Quantitative evaluation of the human subventricular zone," *Brain*, vol. 135, no. 8, p. e221, 2012.

[33] S. A. Van Den Berge, M. E. Van Strien, J. A. Korecka et al., "Reply: Quantitative evaluation of the human subventricular zone," *Brain*, vol. 135, no. 8, p. e222, 2012.

[34] M. Zhao, S. Momma, K. Delfani et al., "Evidence for neurogenesis in the adult mammalian substantia nigra," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 13, pp. 7925–7930, 2003.

[35] Z. Ding, V. Mathur, P. H. Ho et al., "Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation," *The Journal of Experimental Medicine*, vol. 211, pp. 189–198, 2014.

[36] M. W. Marllat, J. Bauer, E. Aronica et al., "Proliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition," *Neural Plasticity*. In press.

[37] K. Imamura, N. Hishikawa, K. Ono et al., "Cytokine production by activated microglia and decrease in neurotrophic factors of
neurons in the hippocampus of Lewy body disease brains," Acta Neuropathologica, vol. 109, no. 2, pp. 141–150, 2005.

[38] R. M. Z. Reena, M. Mastura, M. A. Siti-Aishah et al., "Minichromosome maintenance protein 2 is a reliable proliferative marker in breast carcinoma," Annals of Diagnostic Pathology, vol. 12, no. 5, pp. 340–343, 2008.

[39] P. J. Lucassen, M. W. Stumpel, Q. Wang, and E. Aronica, "Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients," Neuropsychopharmacology, vol. 58, no. 6, pp. 940–949, 2010.

[40] O. Von Bohlen Und Halbach, "Immunohistological markers for staging neurogenesis in adult hippocampus," Cell and Tissue Research, vol. 329, no. 3, pp. 409–420, 2007.

[41] K. Boekhoom, M. Joels, and P. J. Lucassen, "Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus," Neurobiology of Disease, vol. 24, no. 1, pp. 1–14, 2006.

[42] O. Von Bohlen Und Halbach, "Immunohistological markers for proliferative events, gliogenesis, and neurogenesis within the adult hippocampus," Cell and Tissue Research, vol. 345, no. 1, pp. 1–19, 2011.

[43] K. Hashimoto, K. Araki, M. Osaki et al., "MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications," Pathobiology, vol. 71, no. 4, pp. 193–200, 2004.

[44] A. Fahrner, G. Kann, A. Flubacher et al., "Granule cell dispersion is not accompanied by enhanced neurogenesis in temporal lobe epilepsy patients," Experimental Neurology, vol. 203, no. 2, pp. 320–332, 2007.

[45] S. Bruno and Z. Darzynkiewicz, "Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells," Cell Proliferation, vol. 25, no. 1, pp. 31–40, 1992.

[46] A. Y. Maslov, T. A. Barone, R. J. Plunkett, and S. C. Pruitt, "Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice," Journal of Neuroscience, vol. 24, no. 7, pp. 1726–1733, 2004.

[47] Y. Saka and J. C. Smith, "Spatial and temporal patterns of cell division during early Xenopus embryogenesis," Developmental Biology, vol. 229, no. 2, pp. 307–318, 2001.

[48] P. S. Eriksson, E. Perfilieva, T. Björk-Eriksson et al., "Neurogenesis in the adult human hippocampus," Nature Medicine, vol. 4, no. 11, pp. 1313–1317, 1998.

[49] M. S. Rao, B. Hattiangady, and A. K. Shetty, "The window and mechanisms of major age-related decline in the production of new neurons within the dentate gyrus of the hippocampus," Aging Cell, vol. 5, no. 6, pp. 545–558, 2006.

[50] V. Vedam-Mai, B. Gardner, M. S. Okun et al., "Increased precursor cell proliferation after deep brain stimulation for Parkinson's disease: a human study," PloS ONE, vol. 9, Article ID e88770, 2014.

[51] D. R. Kornack and P. Rakic, "Continuation of neurogenesis in the hippocampus of the adult macaque monkey," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5768–5773, 1999.

[52] K. Stiasny-Kolster, Y. Doerr, J. C. Möller et al., "Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT," Brain, vol. 128, no. 1, pp. 126–137, 2005.

[53] U. Sommer, T. Hummel, K. Cormann et al., "Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT," Movement Disorders, vol. 19, no. 10, pp. 1196–1202, 2004.

[54] E. Bezard, S. Prunier et al., "Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease," Journal of Neuroscience, vol. 21, no. 17, pp. 6853–6861, 2001.

[55] K. Herrup and Y. Yang, "Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?" Nature Reviews Neuroscience, vol. 8, no. 5, pp. 368–378, 2007.

[56] A. J. Harding and G. M. Halliday, "Cortical Lewy body pathology in the diagnosis of dementia," Acta Neuropathologica, vol. 102, no. 4, pp. 355–363, 2001.

[57] R. A. Armstrong, P. T. Kotzbauer, J. S. Perlmuter et al., "A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease," Journal of Neural Transmission, vol. 121, no. 2, pp. 171–181, 2014.

[58] H. M. Gao and J. S. Hong, "Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression," Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008.

[59] K. J. Doorn, A. Goudriaan, C. Blits-Huizinga et al., "Increased amoeboid microglial density in the olfactory bulb of Parkinson's and Alzheimer's patients," Brain Pathology, vol. 24, no. 2, pp. 152–165, 2014.

[60] P. L. McGeer and E. G. McGeer, "Glial reactions in Parkinson's disease," Movement Disorders, vol. 23, no. 4, pp. 474–483, 2008.

[61] K. J. Doorn, T. Moors, B. Drukkerh, W. D. van der Berg, P. J. Lucassen, and A.-M. van Dam, "Microglial phenotypes and Toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients," Acta Neuropathologica Communications, vol. 2, article 90, 2014.

[62] B. Winner, M. Regensburger, S. Schregelmann et al., "Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus," The Journal of Neuroscience, vol. 32, no. 47, pp. 16906–16916, 2012.

[63] L. Crews, H. Mizuno, P. Desplats et al., "α-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice," The Journal of Neuroscience, vol. 28, no. 16, pp. 4250–4260, 2008.

[64] L. J. Lawson, V. H. Perry, and S. Gordon, "Turnover of resident microglia in the normal adult mouse brain," Neuroscience, vol. 48, no. 2, pp. 405–415, 1992.

[65] M. Prinz and A. Mildner, "Microglia in the CNS: immigrants from another world," Glia, vol. 59, no. 2, pp. 177–187, 2011.

[66] D. Gómez-Nicola, N. L. Fransen, S. Suzzi, and V. Hugh Perry, "Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia," Nature Communications, vol. 4, article 1562, 2013.
[70] G. Codolo, N. Plotegher, T. Pozzobon et al., “Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies,” PLoS ONE, vol. 8, no. 1, Article ID e55375, 2013.

[71] C. W. Olanow and P. Brundin, “Parkinson’s disease and α-synuclein: is Parkinson’s disease a prion-like disorder?” Movement Disorders, vol. 28, no. 1, pp. 31–40, 2013.

[72] M. Polymenidou and D. W. Cleveland, “Prion-like spread of protein aggregates in neurodegeneration,” Journal of Experimental Medicine, vol. 209, no. 5, pp. 889–893, 2012.

[73] H. Braak, K. del Tredici, U. Rüb, R. A. I. de Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson’s disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003.

[74] E. C. Hirsch, S. Vyas, and S. Hunot, “Neuroinflammation in Parkinson’s disease,” Parkinsonism and Related Disorders, vol. 18, no. 1, pp. S210–S212, 2012.

[75] H. J. Lee, J. E. Suk, E. J. Bae, and S. J. Lee, “Clearance and deposition of extracellular alpha-synuclein aggregates in microglia,” Biochemical and Biophysical Research Communications, vol. 372, no. 3, pp. 423–428, 2008.

[76] A. D. Reynolds, J. G. Glanzer, I. Kadiu et al., “Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease,” Journal of Neurochemistry, vol. 104, no. 6, pp. 1504–1525, 2008.

[77] C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage, “Mechanisms underlying inflammation in neurodegeneration,” Cell, vol. 140, no. 6, pp. 918–934, 2010.

[78] E. G. Reed-Geaghan, J. C. Savage, A. G. Hise, and G. E. Landreth, “CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation,” The Journal of Neuroscience, vol. 29, no. 38, pp. 11982–11992, 2009.

[79] B. Brawek, B. Schwendele, K. Riester et al., “Impairment of in vivo calcium signaling in amyloid plaque-associated microglia,” Acta Neuropathologica, vol. 127, no. 4, pp. 495–505, 2014.

[80] S. A. Baker, K. A. Baker, and T. Hagg, “Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone,” European Journal of Neuroscience, vol. 20, no. 2, pp. 575–579, 2004.

[81] G. U. Hoglinger, O. Arias-Carrión, B. Ipach, and W. H. Oertel, "Origin of the dopaminergic innervation of adult neurogenic areas," Journal of Comparative Neurology, vol. 522, no. 10, pp. 2336–2348, 2014.

[82] A. J. Eisch and C. D. Mandyam, “Adult neurogenesis: can analysis of cell cycle proteins move us ‘beyond BrdU’?” Current Pharmaceutical Biotechnology, vol. 8, no. 3, pp. 147–165, 2007.

[83] M. A. Curtis, V. F. Low, and R. L. M. Faull, “Neurogenesis and progenitor cells in the adult human brain: a comparison between hippocampal and subventricular progenitor proliferation,” Developmental Neurobiology, vol. 72, no. 7, pp. 990–1005, 2012.

[84] P. Taupin, “BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation,” Brain Research Reviews, vol. 53, no. 1, pp. 198–214, 2007.

[85] A. Ernst, K. Alkass, S. Bernard et al., “Neurogenesis in the Striatum of the adult human brain,” Cell, vol. 156, pp. 1072–1083, 2014.
